Protagonist Therapeutics (PTGX) Income towards Parent Company (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Income towards Parent Company data on file, last reported at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 132.46% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at -$114.7 million (down 304.31% YoY), and the FY2025 full-year result was -$130.1 million, down 147.3% from the prior year.
• Income towards Parent Company improved to $3.8 million in Q1 2026, from -$44.4 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $207.4 million in Q1 2024 to a low of -$66.9 million in Q1 2022.
• A 5-year average of -$5.4 million and a median of -$33.7 million in 2023 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company sank 178.95% in 2022 and jumped 714.87% in 2024, its largest moves.
• Tracing PTGX's Income towards Parent Company over 5 years: stood at -$34.9 million in 2022, then soared by 225.69% to $43.9 million in 2023, then jumped by 199.7% to $131.6 million in 2024, then slumped by 133.72% to -$44.4 million in 2025, then surged by 108.52% to $3.8 million in 2026.
• Business Quant data shows PTGX's Income towards Parent Company at $3.8 million in Q1 2026, -$44.4 million in Q4 2025, and -$39.3 million in Q3 2025.